(Reuters) – Teva Pharmaceuticals said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk’s drug Victoza to treat patients with type 2 diabetes.
The U.S. Food and Drug Administration on Friday tentatively approved London-based Hikma Pharmaceuticals’ version of Victoza, according to the agency’s website.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
Comments